{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:14:14Z","timestamp":1791609254652,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T00:00:00Z","timestamp":1702080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Chronisch entz\u00fcndliche Erkrankungen (\u201eimmune-mediated inflammatory diseases\u201c [IMID]) k\u00f6nnen aufgrund klinischer Gemeinsamkeiten \u00fcberlappen oder gleichzeitig auftreten. Die daraus resultierende Inanspruchnahme von Versorgungsstrukturen wurde bisher nicht fach\u00fcbergreifend untersucht, ist aber f\u00fcr eine optimierte Behandlung der Patienten mit IMID potenziell von Bedeutung.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Analyse epidemiologischer Daten einschlie\u00dflich Inanspruchnahme von Versorgungsleistungen bei Patienten mit ausgew\u00e4hlten IMID: Psoriasis, Psoriasisarthritis (PsA), rheumatoide Arthritis (RA), Spondylitis ankylosans, Colitis ulcerosa, Morbus Crohn und Kollagenosen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>In einer retrospektiven Querschnittanalyse, basierend auf Abrechnungsdaten der gesetzlichen Krankenversicherung (GKV) mit einer Stichprobe von ca.\u00a04\u00a0Mio. Versicherten, wurden die Pr\u00e4valenz o.\u202fg. IMID und die H\u00e4ufigkeit von IMID-Kombinationen anhand dokumentierter Diagnosen (ICD-10 GM) analysiert. Die H\u00e4ufigkeit von Hospitalisierungen und Inanspruchnahmen ambulanter Arztkontakte wurde in vordefinierten Fachdisziplinen (Allgemeinmedizin, Dermatologie, Gastroenterologie, Rheumatologie) erfasst und mit einer alters- und geschlechtsadjustierten Referenzpopulation verglichen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Insgesamt wiesen 188.440 Patienten mindestens eine der analysierten IMID-Diagnosen auf (4,7\u202f%), mit einem Altersgipfel von 61 bis 70Jahren. Die h\u00f6chste Pr\u00e4valenz wurde f\u00fcr die Psoriasis (1,85\u202f%), gefolgt von der rheumatoiden Arthritis (1,38\u202f%) gesehen. Kombinationen mit mindestens einer weiteren IMID kamen insgesamt relativ h\u00e4ufig vor (29\u202f%), wobei dies bei Patienten mit Psoriasisarthritis am h\u00e4ufigsten zu verzeichnen war (82,9\u202f%, wobei hiervon 68,2\u202f% Psoriasis), gefolgt von Spondylitis ankylosans (27,5\u202f%) und Morbus Crohn (21,6\u202f%). Patienten mit IMID wurden im Vergleich zur Referenzpopulation h\u00e4ufiger hospitalisiert und wiesen h\u00e4ufigere Inanspruchnahmen der betrachteten ambulanten Fachdisziplinen auf.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die Studienergebnisse beschreiben, dass IMIDs geh\u00e4uft koexistieren und die Patienten Versorgungsstrukturen verschiedener Fachgebiete vergleichsweise mehr in Anspruch nehmen. Ein multidisziplin\u00e4rer Ansatz k\u00f6nnte die Effizienz der Versorgung steigern, eine Evaluierung steht aus.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00393-023-01459-7","type":"journal-article","created":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T17:01:40Z","timestamp":1702141300000},"page":"578-586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Epidemiologische Daten und medizinische Versorgungssituation von Patienten mit chronischen Entz\u00fcndungserkrankungen in Deutschland","Epidemiological data and medical care situation of patients with chronic inflammatory diseases in Germany"],"prefix":"10.1007","volume":"83","author":[{"given":"Gabriela","family":"Riemekasten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Schmelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Thaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"R\u00f6cken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Bartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Ploner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina C.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Leipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,9]]},"reference":[{"key":"1459_CR1","doi-asserted-by":"crossref","unstructured":"Albrecht K, Binder S, Minden K et\u00a0al (2023) Systematic review to estimate the prevalence of inflammatory rheumatic diseases in Germany. German version. Z\u00a0Rheumatol","DOI":"10.1007\/s00393-022-01302-5"},{"key":"1459_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00393-022-01192-7","volume":"81","author":"K Albrecht","year":"2022","unstructured":"Albrecht\u00a0K, Callhoff\u00a0J, Strangfeld\u00a0A (2022) Is the prevalence of rheumatoid arthritis truly on the rise? Z\u00a0Rheumatol 81:323\u2013327","journal-title":"Z Rheumatol"},{"key":"1459_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00393-017-0294-4","volume":"77","author":"K Albrecht","year":"2018","unstructured":"Albrecht\u00a0K, Luque Ramos\u00a0A, Callhoff\u00a0J et\u00a0al (2018) Outpatient care and disease burden of rheumatoid arthritis: results of a\u00a0linkage of claims data and a\u00a0survey of insured persons. Z\u00a0Rheumatol 77:102\u2013112","journal-title":"Z Rheumatol"},{"key":"1459_CR4","doi-asserted-by":"crossref","unstructured":"Albrecht K, Regierer AC, Strangfeld A et\u00a0al (2023) High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex. RMD Open (9)","DOI":"10.1136\/rmdopen-2022-002960"},{"key":"1459_CR5","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1007\/s12325-019-00964-z","volume":"36","author":"D Aletaha","year":"2019","unstructured":"Aletaha\u00a0D, Epstein\u00a0AJ, Skup\u00a0M et al (2019) Risk of developing additional immune-mediated manifestations: a\u00a0retrospective matched cohort study. Adv Ther 36:1672\u20131683","journal-title":"Adv Ther"},{"key":"1459_CR6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pds.3895","volume":"25","author":"F Andersohn","year":"2016","unstructured":"Andersohn\u00a0F, Walker\u00a0J (2016) Characteristics and external validity of the German health risk institute (HRI) database. Pharmacoepidemiol Drug Saf 25:106\u2013109","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1459_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12178-011-9085-8","volume":"4","author":"SL Arvikar","year":"2011","unstructured":"Arvikar\u00a0SL, Fisher\u00a0MC (2011) Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med 4:123\u2013131","journal-title":"Curr Rev Musculoskelet Med"},{"key":"1459_CR8","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1093\/ibd\/izac003","volume":"28","author":"M Attauabi","year":"2022","unstructured":"Attauabi\u00a0M, Wewer\u00a0MD, Bendtsen\u00a0F et al (2022) Inflammatory bowel diseases affect the phenotype and disease course of coexisting immune-mediated inflammatory diseases: a\u00a0systematic review with meta-analysis. Inflamm Bowel Dis 28:1756\u20131765","journal-title":"Inflamm Bowel Dis"},{"key":"1459_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-015-0698-2","volume":"15","author":"C B\u00e4hler","year":"2015","unstructured":"B\u00e4hler\u00a0C, Huber\u00a0CA, Br\u00fcngger\u00a0B et al (2015) Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a\u00a0claims data based observational study. BMC Health Serv Res 15:1\u201312","journal-title":"BMC Health Serv Res"},{"key":"1459_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00393-019-0619-6","volume":"78","author":"J Braun","year":"2019","unstructured":"Braun\u00a0J, Schwarting\u00a0A, Hammel\u00a0L et al (2019) Medical care situation of patients with ankylosing spondylitis and psoriatic arthritis in Germany : medical care situation of patients with spondyloarthritis (spA): ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from the perspective of rheumatologists in private practice and hospitals in Germany-results of the research project \u201cspA loop-life of outpatients\u201d. Z\u00a0Rheumatol 78:372\u2013381","journal-title":"Z Rheumatol"},{"key":"1459_CR11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00393-019-0619-6","volume":"78","author":"J Braun","year":"2019","unstructured":"Braun\u00a0J, Schwarting\u00a0A, Hammel\u00a0L et\u00a0al (2019) Versorgungssituation von Patienten mit ankylosierender Spondylitis und Psoriasisarthritis in Deutschland. Z\u00a0Rheumatol 78:372\u2013381","journal-title":"Z Rheumatol"},{"key":"1459_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00393-019-0669-9","volume":"78","author":"J Callhoff","year":"2019","unstructured":"Callhoff\u00a0J, Albrecht\u00a0K, Hoffmann\u00a0F et\u00a0al (2019) Reality of care for musculoskeletal diseases at the population level. Z\u00a0Rheumatol 78:73\u201379","journal-title":"Z Rheumatol"},{"key":"1459_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.5562","volume":"32","author":"J Callhoff","year":"2023","unstructured":"Callhoff\u00a0J, Albrecht\u00a0K, Marschall\u00a0U et al (2023) Identification of rheumatoid arthritis in German claims data using different algorithms: validation by cross-sectional patient-reported survey data. Pharmacoepidemiology and Drug 32:517\u2013525","journal-title":"Pharmacoepidemiology and Drug"},{"key":"1459_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates\u00a0LC, Soriano\u00a0ER, Corp\u00a0N et\u00a0al (2022) Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479","journal-title":"Nat Rev Rheumatol"},{"key":"1459_CR15","doi-asserted-by":"crossref","unstructured":"Crossfield SSR, Marzo-Ortega H, Kingsbury SR et al (2021) Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades. RMD Open (7)","DOI":"10.1136\/rmdopen-2021-001888"},{"key":"1459_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3899\/jrheum.091461","volume":"85","author":"H El-Gabalawy","year":"2010","unstructured":"El-Gabalawy\u00a0H, Guenther\u00a0LC, Bernstein\u00a0CN (2010) Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J\u00a0Rheumatol Suppl 85:2\u201310","journal-title":"J Rheumatol Suppl"},{"key":"1459_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00393-018-0481-y","volume":"77","author":"C Fiehn","year":"2018","unstructured":"Fiehn\u00a0C, Holle\u00a0J, Iking-Konert\u00a0C et al (2018) S2e guideline: treatment of rheumatoid arthritis with disease-modifying drugs. Z\u00a0Rheumatol 77:35\u201353","journal-title":"Z Rheumatol"},{"key":"1459_CR18","first-page":"ii14","volume":"64","author":"D Gladman","year":"2005","unstructured":"Gladman\u00a0D, Antoni\u00a0C, Mease\u00a0P et\u00a0al (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64:ii14\u2013ii17","journal-title":"Ann Rheum Dis"},{"key":"1459_CR19","doi-asserted-by":"crossref","unstructured":"Gordon H, Burisch J, Ellul P et\u00a0al (2023) ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J\u00a0Crohns Colitis","DOI":"10.1093\/ecco-jcc\/jjad108"},{"key":"1459_CR20","first-page":"445","volume":"20","author":"I Hansen","year":"2022","unstructured":"Hansen\u00a0I, Augustin\u00a0M, Schafer\u00a0I et al (2022) Epidemiology of skin diseases in Germany: systematic review of the current state of research\u2014part 2: non-infectious skin diseases. J\u00a0Dtsch Dermatol Ges 20:445\u2013455","journal-title":"J Dtsch Dermatol Ges"},{"key":"1459_CR21","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3109\/00365521.2014.962605","volume":"49","author":"R Hein","year":"2014","unstructured":"Hein\u00a0R, Koster\u00a0I, Bollschweiler\u00a0E et al (2014) Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a\u00a0large insurance-based regional cohort. Scand J Gastroenterol 49:1325\u20131335","journal-title":"Scand J Gastroenterol"},{"key":"1459_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00393-016-0088-0","volume":"75","author":"S Hense","year":"2016","unstructured":"Hense\u00a0S, Ramos\u00a0AL, Callhoff\u00a0J et\u00a0al (2016) Pr\u00e4valenz der rheumatoiden Arthritis in Deutschland auf Basis von Kassendaten. Z\u00a0Rheumatol 75:819\u2013827","journal-title":"Z Rheumatol"},{"key":"1459_CR23","first-page":"438","volume":"50","author":"DR Jadon","year":"2023","unstructured":"Jadon\u00a0DR, Corp\u00a0N, Van Der Windt\u00a0DA et\u00a0al (2023) Management of concomitant inflammatory bowel disease or uveitis in patients with psoriatic arthritis: an updated review informing the 2021 GRAPPA treatment recommendations. J\u00a0Rheumatol 50:438\u2013450","journal-title":"J Rheumatol"},{"key":"1459_CR24","doi-asserted-by":"publisher","first-page":"101692","DOI":"10.1016\/j.berh.2021.101692","volume":"35","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya\u00a0P, Chakradhar\u00a0R, Ogdie\u00a0A (2021) The epidemiology of psoriatic arthritis: a\u00a0literature review. Best Pract Res Clin Rheumatol 35:101692","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1459_CR25","unstructured":"Leipe J, Schmelz R, Riemekasten G et al (2023) Immune-mediated inflammatory diseases in Germany : a\u00a0cross-sectional analysis of comorbidities and pharmacotherapy. Z\u00a0Rheumatol"},{"key":"1459_CR26","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-021-00603-1","volume":"21","author":"IB Mcinnes","year":"2021","unstructured":"Mcinnes\u00a0IB, Gravallese\u00a0EM (2021) Immune-mediated inflammatory disease therapeutics: past, present and future. Nat Rev Immunol 21:680\u2013686","journal-title":"Nat Rev Immunol"},{"key":"1459_CR27","first-page":"599","volume":"11","author":"U M\u00fcller-Ladner","year":"2020","unstructured":"M\u00fcller-Ladner\u00a0U, De Groot\u00a0K (2020) Pathophysiologie von chronisch-entz\u00fcndlichen Erkrankungen \u2013 Ansatzpunkte f\u00fcr neue Therapieans\u00e4tze. Landes\u00e4rztekammer Hessen. Hess \u00c4rztebl 11:599\u2013606","journal-title":"Hess \u00c4rztebl"},{"key":"1459_CR28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1055\/s-0030-1252022","volume":"73","author":"I Schafer","year":"2011","unstructured":"Schafer\u00a0I, Rustenbach\u00a0SJ, Radtke\u00a0M et\u00a0al (2011) Epidemiology of psoriasis in Germany\u2014analysis of secondary health insurance data. Gesundheitswesen 73:308\u2013313","journal-title":"Gesundheitswesen"},{"key":"1459_CR29","first-page":"286","volume-title":"BARMER GEK Gesundheitswesen aktuell","author":"A Stallmach","year":"2012","unstructured":"Stallmach\u00a0A, H\u00e4user\u00a0W, L\u2019hoest\u00a0H et\u00a0al (2012) Die chronisch entz\u00fcndlichen Darmerkrankungen Morbus Crohn und Colitis ulcerosa: Herausforderungen an die Versorgung. In: BARMER GEK Gesundheitswesen aktuell, S\u00a0286\u2013309"},{"key":"1459_CR30","volume-title":"Versorgungsatlas-Bericht Nr","author":"A Steffen","year":"2017","unstructured":"Steffen\u00a0A, Holstiege\u00a0J, Goffrier\u00a0B et al (2017) Epidemiologie der rheumatoiden Arthritis in Deutschland \u2013 eine Analyse anhand bundesweiter vertrags\u00e4rztlicher Abrechnungsdaten. In: Versorgungsatlas-Bericht Nr, Bd. 17\/08. Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland, Zi, Berlin"},{"key":"1459_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-64732-8","volume":"10","author":"N Ziade","year":"2020","unstructured":"Ziade\u00a0N, El Khoury\u00a0B, Zoghbi\u00a0M et\u00a0al (2020) Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study. Sci Rep 10:1\u201310","journal-title":"Sci Rep"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01459-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01459-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T12:04:17Z","timestamp":1727697857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01459-7"}},"subtitle":["Real-World-Evidenz zu Pr\u00e4valenz, Erkrankungskombinationen, Versorgung","Real-world evidence on prevalence, disease combinations, care"],"short-title":[],"issued":{"date-parts":[[2023,12,9]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1459"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01459-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,9]]},"assertion":[{"value":"19 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Riemekasten, R.\u00a0Schmelz, K.\u00a0Sch\u00e4kel, D.\u00a0Thaci, S.\u00a0Schreiber, M.\u00a0R\u00f6cken, H.\u00a0Bartz, T.\u00a0Ploner, X.\u00a0Liao, V.\u00a0Weber, K.C.\u00a0Manz, H.\u00a0Burkhardt und J.\u00a0Leipe verzeichnen Vortragshonorare von und eine Beratert\u00e4tigkeit f\u00fcr die Janssen-Cilag GmbH oder sind Mitarbeiter der Janssen-Cilag GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}